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A commentary on
Acute hemorrhagic leukoencephalitis (Weston-Hurst syndrome) in a patient with relapse-
remitting multiple sclerosis
by Yildiz Ö, Pul R, Raab P, Hartmann C, Skripuletz T, Stangel M. J Neuroinflammation (2015) 12:175. 
doi: 10.1186/s12974-015-0398-1
Recently, Yildiz et al. reported the occurrence of acute hemorrhagic leukoencephalitis (AHLE) in 
a patient with pluriannual relapse-remitting multiple sclerosis (MS) after 1  month of high-dose 
interferon-β-1a treatment. The authors raised the question whether this case may be a hyperacute 
form of acute disseminated encephalomyelitis (ADEM) or a rare hemorrhagic evolution of tumefac-
tive demyelination (TD), both unusual in the course of MS (1). They concluded that AHLE occurrence 
was unrelated to the underlying MS since hemorrhage has not been found in neuropathological pat-
terns of both MS and TD. Although two published case reports of TD with hemorrhage in the course 
of fingolimod and natalizumab therapies (brain biopsy was not performed) have been mentioned in 
the paper, the potential predisposing effect of interferon-β therapy on the AHLE development has 
not been hypothesized.
However, since the symmetrical basal ganglia hemorrhagic lesions in this case were developed 
after the first month of high-dose interferon-β-1a treatment (1), the therapy influence should be 
taken into account. There were previously reported brain hemorrhages during treatment with both 
interferon-β in MS and interferon-α in HCV hepatitis (2), as well as a case of TD in pediatric MS 
patient under interferon-β therapy (3). Moreover, a thrombotic thrombocytopenic purpura with 
thrombotic microangiopathy and hemolytic–uremic syndrome has been recently included as a rare 
interferon-β adverse event in its package leaflet by the EMA. We also found in a cohort of 187 
MS patients that a mild thrombocytopenia was more frequent (p = 0.02) in patients on high-dose 
interferon-β therapy (16%) compared to those on treatment with low-dose interferon-β (3.1%), other 
drugs (5%), including glatiramer acetate (4%), natalizumab (9.1%), and fingolimod (0%), or untreated 
patients (2.2%) (4). High-dose interferon-β therapy was associated with more than eightfold increase 
in the risk for thrombocytopenia (odds ratio 8.60, 95% confidence interval: 1.01–74.48).
The type I interferon-α/β rapidly produced during infection has antiviral activity and plays a key 
role in innate immunity, which represents the non-specific defense against infections and tissue 
damage acting through its essential processes including inflammation and blood coagulation (5). 
Thrombocytopenia is a frequent complication of viral infections, thus, we supposed that the interferon-
activated innate inflammatory–thrombotic processes could lead to the increased platelets consump-
tion. Moreover, it was recently demonstrated that mice treated with polyinosinic:polycytidylic acid, 
strong interferon-β inducer, showed thrombocytopenia and platelet hemostatic and inflammatory 
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dysfunction, associated with abnormal megakaryocytes distribu-
tion in the bone marrow niches and directly correlated with the 
plasmatic and bone marrow interferon-β levels (6).
Indeed, platelets cooperate not only in hemostasis and thrombo-
sis but also in inflammation, immunity, and tissue repair creating a 
link between innate and adaptive immunity (7). Platelet-activating 
factor (PAF), secreted by the cooperation of platelets and leuko-
cytes, is a potent platelet activator and chemotactic stimulant for 
inflammatory cells and contributes to the early breakdown of the 
blood–brain barrier (BBB) through endothelial junction disrup-
tion (7). The chronic platelet activation is well established in MS, 
and PAF receptors are upregulated in MS lesions (7). Moreover, 
the release of adhesion molecule PECAM-1 to the circulation and 
associated leukocyte infiltration are likely consequent to platelet 
interaction with leukocytes at BBB endothelium (7). Furthermore, 
activated platelets amplify coagulation, whereas activated coagula-
tion stimulates platelets (7). Recent experimental evidences of the 
coagulation cascade contribution in inflammatory, degenerative, 
and repair processes in the central nervous system (CNS) further 
support the previous data on the presence of several coagulation 
factors in MS lesions (8).
In the AHLE case described, a MRI-guided biopsy showed 
some partially thrombosed vessels with perivascular hemorrhagic 
necrosis, severe edema, and prevalently neutrophil inflammatory 
infiltrate, although a thrombocytopenia was not reported (1).
Since ADEM and AHLE are frequently preceded by infec-
tions, Yildiz et al. commented that the cross-reactivity between 
human myelin antigens and viral or bacterial antigens likely 
induce an excessive immunological response and mentioned an 
AHLE murine model determined by a strong activation of CD8+ 
T cells in C57BL/6 mice leading to hemorrhagic demyelination 
within 24 h following injecting of the VP2121–130 viral capsid 
peptide of the Theiler’s murine encephalomyelitis virus (1). In 
this murine model, a determinant role of hematopoietic factors 
in the onset of brain microhemorrhage and vascular permeabil-
ity was subsequently showed because hemorrhage susceptibility 
of C57BL/6 mice was transferable with their bone marrow to 
hemorrhage-resistant 129 SvIm mice having indistinguishable 
CD8+ T-cell responses (9). Megakaryocytes producing platelets 
could be one among the others of these hematopoietic factors. 
Furthermore, injection of interferon-α/β was found to prolong 
the proliferation and expansion of antigen-specific CD8+ T cells 
during cross-priming, representing an additional mechanism 
by which the innate response to infection promotes adaptive 
immunity (10).
Undoubtedly, cerebral hemorrhagic lesions under or without 
interferon therapy are a very uncommon event in MS, likely deter-
mined by an exceptional coincidence of local and/or systemic 
predisposing conditions (probable concomitant infections, etc.). 
However, using T2*-weighted 3-T MRI, Zivadinov et  al. have 
found a significant higher frequency of cerebral microbleeds in 
445 MS patients compared to 177 healthy controls, particularly in 
subjects ≥50 years of age (p = 0.01, 19.8% vs. 7.4%, respectively) 
but similar to that of 51 patients with other neurological diseases 
(11). This finding further supports the essential role of inflamma-
tion and coagulation, both arms of innate immunity, in many if not 
all CNS inflammatory degenerative diseases approaching them 
in common baseline pathogenetic mechanism. The interferon-β 
activating the different patterns of innate immunity could lead 
in particular conditions to increased inflammatory–thrombotic 
processes up to hemorrhagic manifestations in the CNS.
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